JP2017528468A - ガラクトース操作型免疫グロブリン１抗体 - Google Patents

ガラクトース操作型免疫グロブリン１抗体 Download PDF

Info

Publication number
JP2017528468A
JP2017528468A JP2017513506A JP2017513506A JP2017528468A JP 2017528468 A JP2017528468 A JP 2017528468A JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017528468 A JP2017528468 A JP 2017528468A
Authority
JP
Japan
Prior art keywords
antibodies
antibody
population
relative frequency
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017513506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528468A5 (enExample
Inventor
セバスチャン マリク
セバスチャン マリク
ディートマル ロイシュ
ディートマル ロイシュ
アルフレッド シュヌエリガー
アルフレッド シュヌエリガー
マックス エル． テハダ
マックス エル． テハダ
マルコ トマン
マルコ トマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017528468A publication Critical patent/JP2017528468A/ja
Publication of JP2017528468A5 publication Critical patent/JP2017528468A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017513506A 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体 Withdrawn JP2017528468A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14184201 2014-09-10
EP14184201.3 2014-09-10
US201462095912P 2014-12-23 2014-12-23
US62/095,912 2014-12-23
PCT/EP2015/070285 WO2016037947A1 (en) 2014-09-10 2015-09-04 Galactoengineered immunoglobulin 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156251A Division JP2021006540A (ja) 2014-09-10 2020-09-17 ガラクトース操作型免疫グロブリン１抗体

Publications (2)

Publication Number Publication Date
JP2017528468A true JP2017528468A (ja) 2017-09-28
JP2017528468A5 JP2017528468A5 (enExample) 2018-09-27

Family

ID=51518624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513506A Withdrawn JP2017528468A (ja) 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体

Country Status (5)

Country Link
US (2) US20170253661A1 (enExample)
EP (2) EP3191527B1 (enExample)
JP (1) JP2017528468A (enExample)
CN (2) CN114181312A (enExample)
WO (1) WO2016037947A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500371A (ja) * 2018-09-11 2022-01-04 アムジエン・インコーポレーテツド 抗体依存性細胞介在性細胞傷害の調節方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6850351B2 (ja) 2016-12-21 2021-03-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学
EP3559250A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
AU2017381657B2 (en) * 2016-12-21 2020-07-23 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
EP4041773A1 (en) * 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US11975066B2 (en) 2020-08-31 2024-05-07 SAB Biotherapeutics, Inc. Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4119672A1 (en) * 2021-07-14 2023-01-18 Sartorius Stedim Cellca GmbH Method of modulating the extent of galactosylation of proteins in mammalian producer cells
CN114167060B (zh) * 2021-11-25 2022-08-05 辽宁师范大学 一种肝癌生物标志物及检测肝癌的试剂盒
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
ME01775B (me) * 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
CN101646775B (zh) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011149999A2 (en) * 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2012020065A1 (en) * 2010-08-10 2012-02-16 Glycotope Gmbh Fab-glycosylated antibodies
BR112014003110A2 (pt) * 2011-08-10 2018-10-09 Lab Francais Du Fractionnement composição, método para produção de uma população altamente galactosilada de anticorpos, células epiteliais de glândula mamária e mamífero não humano tramsgênico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504569A (ja) * 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500371A (ja) * 2018-09-11 2022-01-04 アムジエン・インコーポレーテツド 抗体依存性細胞介在性細胞傷害の調節方法

Also Published As

Publication number Publication date
US20200325245A1 (en) 2020-10-15
CN106687481A (zh) 2017-05-17
WO2016037947A1 (en) 2016-03-17
EP3191527A1 (en) 2017-07-19
EP3191527B1 (en) 2020-01-15
EP3567056A1 (en) 2019-11-13
CN106687481B (zh) 2022-03-22
US20170253661A1 (en) 2017-09-07
CN114181312A (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
US20200325245A1 (en) Galactoengineered immunoglobulin 1 antibodies
EP3461843B1 (en) Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile
Jefferis Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
US9120856B2 (en) Anti-CD19 antibody having ADCC function with improved glycosylation profile
US20080226635A1 (en) Antibodies against insulin-like growth factor I receptor and uses thereof
TWI780097B (zh) 於活體外進行抗體之糖基化工程
WO2013095738A2 (en) Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
JP2010514448A (ja) アシアリル化免疫グロブリンを生成するための方法およびベクター
KR20080113233A (ko) 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
JP2021006540A (ja) ガラクトース操作型免疫グロブリン１抗体
HK1241889A1 (en) Galactoengineered immunoglobulin 1 antibodies
CN101466402A (zh) 糖基化改造的抗体治疗
HK1134829A (en) Antibodies against insulin-like growth factor i receptor and uses thereof
HK40011889A (en) In vitro glycoengineering of antibodies
HK1217338B (zh) 具有adcc和cdc功能及改善的糖基化特徵的抗-cd19抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200520

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200917

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210326

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210607

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210705

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210819

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211118

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220221